signific
advanc
made
allogen
transplant
adult
pediatr
transplant
recipi
past
year
correspond
dramat
declin
treatmentrel
mortal
trm
cumul
incid
trm
year
follow
unrel
donor
transplant
decreas
children
acut
leukemia
primari
indic
transplant
pediatr
popul
macmillan
et
al
improv
condit
regimen
support
care
human
leukocyt
antigen
hla
test
associ
increment
improv
surviv
period
particular
manag
infecti
noninfecti
organ
complic
chang
dramat
improv
sensit
diagnost
test
pathogen
tremend
improv
understand
organ
complic
two
organ
complic
particular
pulmonari
hepat
major
focu
investig
past
sever
decad
introduct
tumor
necrosi
factor
tnf
inhibitor
manag
acut
noninfecti
lung
injuri
introduct
endotheli
stabil
agent
defibrotid
manag
hepat
venoocclus
diseas
major
advanc
field
pulmonari
toxic
infecti
noninfecti
develop
hematopoiet
cell
transplant
hct
recipi
account
nearli
transplantrel
death
clark
et
al
crawford
hackman
weiner
et
al
quabeck
crawford
et
al
kantrow
et
al
afessa
et
al
despit
advanc
treat
opportunist
organ
infecti
lung
injuri
remain
signific
problem
particularli
patient
graftversushost
diseas
gvhd
individu
delay
immun
reconstitut
hand
noninfecti
lung
injuri
either
acut
chronic
depend
upon
time
occurr
posttranspl
rate
diseas
progress
acut
lung
injuri
may
alloreact
nonalloimmun
secondari
cardiogen
shock
chemoradiotherapi
effect
chronic
lung
injuri
may
obstruct
restrict
natur
depend
upon
pathogenesi
lung
injuri
pattern
holland
et
al
schultz
et
al
crawford
et
al
sullivan
et
al
sanchez
et
al
badier
et
al
quigley
et
al
section
review
definit
risk
factor
pathogenesi
lung
injuri
occur
hct
respiratori
distress
progress
rapidli
establish
time
coordin
care
hematologyoncolog
pulmonari
often
intensivist
team
essenti
optim
outcom
determin
sever
respiratori
dysfunct
includ
assess
need
supplement
oxygen
support
overal
fluid
balanc
renal
function
cardiac
output
follow
radiograph
imag
gener
initi
chest
xray
ct
scan
identifi
presenc
lobar
multilobar
diffus
pulmonari
infiltr
fig
find
may
impact
decisionmak
process
nondiagnost
absenc
obviou
cardiac
failur
iatrogen
fluid
overload
bronchoscopi
bronchoalveolar
lavag
bal
consid
infiltr
present
bal
sampl
sent
number
diagnost
test
determin
potenti
presenc
commun
hospit
acquir
opportunist
infect
besid
bacteri
fungal
cytolog
stain
quantit
cultur
perform
bal
fluid
diagnost
purpos
addit
direct
fluoresc
antibodi
stain
centrifug
cultur
shell
vial
polymeras
chain
reaction
pcr
assay
may
also
use
isolatingidentifi
variou
viral
pathogen
role
bal
hct
recipi
remain
matter
debat
diagnost
yield
rang
variou
report
huaringa
et
al
mani
case
patient
refer
bal
sever
day
symptom
empir
antibiot
therapi
well
establish
empir
antibiot
manag
report
provid
inadequ
coverag
patient
pathogen
identifi
subsequ
bal
ascioglu
et
al
prasoon
et
al
furthermor
prolong
empir
antibiot
may
diminish
growth
potenti
pathogen
limit
subsequ
util
bronchoscop
procedur
retrospect
studi
patient
underw
bal
within
first
day
posthct
md
anderson
cancer
center
overal
yield
bal
yield
time
greater
among
patient
bal
perform
within
initi
day
clinic
present
addit
pneumoniaassoci
death
three
time
higher
vs
patient
undergo
late
bronchoscopi
follow
day
clinic
symptom
shannon
et
al
yanik
colleagu
examin
bronchoscopi
procedur
complet
patient
receiv
hct
univers
michigan
yanik
et
al
bal
specimen
collect
first
day
hct
posit
infect
diagnost
yield
increas
day
henc
major
hct
patient
requir
bal
within
first
day
may
categor
idiopath
pneumonia
syndrom
ip
signific
number
individu
evid
infect
bal
result
chang
medic
manag
approxim
case
factor
contribut
infecti
pneumon
follow
hct
may
includ
suppress
laryng
cough
reflex
impair
remov
respiratori
secret
due
decreas
mucociliari
clearanc
airway
obstruct
impair
humor
cellular
defens
mechan
quantit
andor
qualit
defect
neutrophil
lymphoid
function
allow
nonpathogen
organ
ultim
becom
invas
pathogen
lung
kg
child
expos
approxim
liter
inhal
air
everi
hour
number
organ
inorgan
particl
potenti
pathogen
organ
process
respiratori
tract
day
countless
fine
balanc
exist
organ
becom
true
pathogen
remain
commensur
often
depend
upon
quantiti
inoculum
receiv
hostdefens
factor
outlin
infecti
pneumon
may
subdivid
associ
either
interstiti
parenchym
involv
common
pathogen
caus
interstiti
pneumon
includ
communityacquir
respiratori
virus
eg
parainfluenza
respiratori
syncyti
viru
rsv
influenza
metapneumonia
mycoplasma
opportunist
pathogen
pneumocysti
jiroveci
pcp
wherea
bacteri
fungal
pathogen
frequent
associ
parenchym
chang
cmv
pneumon
remain
signific
caus
morbid
mortal
follow
allogen
hct
absenc
cmv
prevent
strategi
eg
preemptiv
monitor
cmv
plasma
pcr
antigenemia
univers
prophylaxi
cmv
pneumon
may
develop
first
day
follow
hct
peak
incid
approxim
week
current
era
cmv
infect
occur
monitor
prophylaxi
period
end
cmv
pneumon
patient
chronic
gvhd
also
well
document
boeckh
ljungman
osarogiagbon
et
al
avail
improv
antivir
therapi
mortal
rate
associ
cmv
pneumon
declin
significantli
recent
year
reusser
risk
factor
develop
cmv
diseas
includ
presenc
acut
gvhd
recipi
cmv
seroposit
transplant
hematolog
malign
use
antithymocyt
globulin
transplant
process
osarogiagbon
et
al
ljungman
et
al
radiolog
manifest
cmv
rang
diffus
interstiti
opac
widespread
air
space
consolid
shimada
et
al
histopatholog
remain
gold
standard
identif
cmv
pulmonari
diseas
though
molecular
techniqu
excel
sensit
detect
infect
may
less
specif
regard
identifi
cmv
pneumon
potenti
polymicrobi
superinfect
anoth
concern
transplant
patient
cmv
pulmonari
diseas
given
multipl
issu
often
involv
patient
activ
cmv
infect
includ
concurr
use
system
corticosteroid
prolong
empir
antibiot
usag
respiratori
syncyti
viru
rsv
singlestrand
envelop
rna
viru
present
selflimit
upper
respiratori
tract
infect
immunocompet
individu
potenti
fatal
pneumon
immunocompromis
patient
ebbert
limper
outbreak
patient
undergo
allogen
hct
associ
mortal
rate
high
englund
et
al
harrington
et
al
unit
state
onset
rsv
infect
typic
begin
novemb
continu
approxim
week
organ
highli
contagi
transmiss
occur
primarili
surfac
contamin
viralladen
nasal
oral
secret
even
immunocompet
patient
nativ
memori
respons
incomplet
allow
repeat
infect
overal
virul
agent
place
immunocompromis
patient
particular
risk
fatal
lower
respiratori
tract
infect
season
period
ebbert
limper
radiograph
patchi
alveolar
diffus
interstiti
infiltr
may
seen
clinic
affect
patient
may
exhibit
profound
dyspnea
hypoxemia
without
concurr
upper
respiratori
tract
symptom
less
patient
lower
tract
involv
preced
concurr
nasopharyng
symptom
ebbert
limper
harrington
et
al
use
aerosol
ribavirin
gday
use
small
particl
gener
result
decreas
rsv
shed
clinic
efficaci
proven
ebbert
limper
boeckh
et
al
palivizumab
may
consid
prophylaxi
option
adult
lower
respiratori
tract
diseas
hynicka
ensor
clinic
impact
recent
describ
virus
includ
human
metapneumoviru
nonsar
human
coronavirus
yet
clear
human
metapneumoviru
hmpv
paramyxoviru
recent
recogn
first
human
pathogen
within
genu
metapneumoviru
van
den
hoogen
et
al
viru
first
identifi
netherland
recent
report
potenti
pathogen
allogen
transplant
recipi
englund
et
al
bone
marrow
transplant
set
infect
patient
typic
present
within
first
day
posttranspl
exhibit
clinic
radiograph
find
similar
appear
ip
rapid
progress
respiratori
symptom
may
occur
median
day
report
initi
oxygen
support
death
englund
et
al
clinic
spectrum
hmpv
caus
interstiti
pneumonia
posttranspl
remain
ill
defin
issu
frequenc
asymptomat
shed
improv
detect
method
treatment
strategi
investig
reactiv
latent
virus
especi
herp
famili
adenoviru
may
also
clinic
mimic
interstiti
pneumon
shield
et
al
howev
vast
major
case
clinic
symptom
relat
system
involv
manifest
sign
diseas
organ
includ
abdomin
pain
elev
serum
hepat
transaminas
cmv
varicella
zoster
viru
adenoviru
oral
mucos
involv
herp
simplex
virus
bacteri
pneumonia
typic
present
alveolar
parenchym
fill
infiltr
concurr
fever
clinic
symptom
chest
pain
tachypnea
cough
pneumonia
due
bacteria
common
preengraft
period
includ
infect
gramposit
staphylococcu
streptococcu
speci
wide
rang
gramneg
organ
factor
impact
risk
earli
bacteri
pneumonia
includ
oralpharyng
mucos
focal
diffus
enter
aspir
risk
due
influenc
opiat
sed
catheterrel
risk
pneumonia
due
gramneg
organ
pseudomona
aeruginosa
klebsiella
pneumonia
acinetobact
escherichia
coli
enterobact
commonli
report
within
first
day
posttranspl
particular
concern
patient
concurr
gastrointestin
gvhd
martinpena
et
al
later
onset
bacteri
pneumonia
follow
day
posthct
uncommon
patient
concurr
chronic
gvhd
especi
promin
patient
bronchiol
obliteran
syndrom
bo
system
corticosteroid
chronic
gvhd
manag
fungi
histor
classifi
either
yeast
candida
trichosporon
cryptococcu
mold
mold
subdivid
septat
hypha
aspergillu
scedosporium
fusarium
histoplasma
penicillium
asept
hypha
mucor
rhizopu
fungi
rare
caus
acut
infect
immunocompet
host
candida
speci
exampl
commens
flora
nasopharyng
tract
skin
rare
caus
lower
respiratori
tract
invas
immunocompromis
host
candid
infect
candidemia
commonli
seen
breakdown
epitheli
mucos
barrier
occur
conjunct
concurr
use
empir
antibacteri
agent
erad
normal
bacteri
flora
tissu
cultur
requir
establish
diagnosi
invas
candida
bronchoalveolar
lavag
sputum
cultur
poor
predictor
invas
pulmonari
candid
infect
contrast
invas
fungal
infect
pathogen
mold
common
caus
pneumonia
posttranspl
set
invas
aspergillu
infect
occur
allogen
transplant
recipi
aspergillu
pneumonia
report
median
day
posttranspl
overal
surviv
invas
aspergillu
report
less
grow
et
al
risk
factor
develop
aspergillu
pneumonia
includ
prolong
corticosteroid
usag
mgkgday
histori
recent
cytomegaloviru
cmv
infect
prolong
neutropenia
grow
et
al
garciavid
et
al
combin
neutropenia
impair
tcell
function
abnorm
glucos
metabol
addit
risk
invas
fungi
definit
invas
fungi
establish
distinguish
colon
actual
infect
invas
fungal
infect
classifi
proven
probabl
possibl
proven
infect
requir
histolog
confirm
posit
tissu
cultur
probabl
infect
requir
host
factor
clinic
andor
fluid
cultur
consist
invas
fungu
de
pauw
et
al
current
avail
test
serum
fungal
marker
betaglucan
galactomannan
could
also
use
differenti
colon
invas
infect
candida
aspergillu
speci
respect
radiograph
featur
invas
fungi
heterogen
small
larg
nodul
groundglass
opacif
cavitari
lesion
treeinbud
appear
halo
sign
observ
chest
radiograph
comput
tomographi
ct
treatment
invas
fungi
make
use
uniqu
biolog
organ
fungi
contain
cell
membran
ergosterol
cell
wall
betaglucan
target
antifung
therapi
voriconazol
provid
effect
therapi
wide
rang
pathogen
fungi
exclud
mucor
speci
posaconazol
lipid
formul
amphotericin
b
provid
coverag
mucor
addit
coverag
aspergillu
candida
speci
clinician
initi
voriconazol
antifung
azol
therapi
mind
impact
cytochrom
drug
includ
calcineurin
inhibitor
tacrolimu
cyclosporin
mtor
inhibitor
sirolimu
voriconazol
initi
dose
tacrolimu
cyclosporin
reduc
even
greater
dose
reduct
sirolimu
given
conjunct
voriconazol
initi
describ
chemotherapyassoci
pulmonari
toxic
report
associ
multipl
chemotherapeut
busulfan
agent
includ
bcnu
busulfan
cyclophosphamid
melphalan
particular
bcnurel
lung
injuri
acut
onset
develop
within
first
month
follow
hct
patient
receiv
therapi
aronin
et
al
clinic
bcnurel
lung
injuri
associ
nonproduct
cough
increas
dyspnea
context
rapidli
progress
bilater
interstiti
infiltr
chest
radiograph
ct
pulmonari
function
test
reveal
restrict
pattern
lung
injuri
diminish
forc
vital
capac
total
lung
capac
note
lane
et
al
pathogenesi
bcnurel
lung
injuri
ill
defin
though
increas
product
fibrogen
factor
plateletderiv
growth
insulinlik
growth
factor
transform
growth
implic
shen
et
al
treatment
puls
dose
corticosteroid
earli
clinic
cours
significantli
decreas
morbid
mortal
associ
condit
key
success
outcom
untreat
recogn
late
clinic
cours
sever
pulmonari
fibrosi
may
develop
shen
et
al
busulfan
either
alon
combin
cytotox
agent
also
implic
posttranspl
lung
dysfunct
howev
use
pharmacokinet
target
busulfan
dose
decreas
incid
acut
lung
injuri
similar
bcnu
administr
increas
pulmonari
toxic
note
patient
receiv
prior
mediastin
radiotherapi
follow
either
autolog
allogen
hct
boll
et
al
trali
one
lead
caus
mortal
follow
infus
plasmacontain
blood
product
estim
occur
transfus
silliman
et
al
kopko
et
al
plasmacontain
blood
product
includ
whole
blood
pack
red
blood
cell
prbc
fresh
frozen
plasma
ffp
platelet
cryoprecipit
granulocyt
immun
globulin
infus
stem
cell
product
link
develop
trali
albumin
sole
except
swanson
et
al
diagnosi
base
upon
clinic
symptom
acut
onset
dyspnea
respiratori
distress
typic
occur
hour
transfus
chest
radiograph
reveal
diffus
pulmonari
infiltr
reflect
edema
increas
pulmonari
vascular
permeabl
patholog
neutrophil
infiltr
overexpress
neutrophilrel
cytokin
chemokin
link
develop
mortal
rate
approxim
trali
account
transfusionrel
death
treatment
gener
support
discontinu
blood
product
corticosteroid
administr
forc
diuresi
respiratori
support
result
recoveri
within
day
major
patient
case
donor
antibodi
direct
hla
class
ii
epitop
recipi
hematopoiet
cell
identifi
primari
caus
trali
event
rare
case
antibodi
may
present
recipi
plasma
may
direct
transfus
donor
leukocyt
kopko
et
al
kao
et
al
use
high
plasma
volum
blood
product
alloimmun
donor
includ
apheresi
stem
cell
product
platelet
associ
high
risk
develop
trali
reesink
et
al
ip
refer
acut
lung
injuri
occur
posthct
associ
diffus
alveolar
damag
absenc
lower
respiratori
tract
infect
nation
institut
health
nih
workshop
propos
broad
definit
ip
definit
recent
updat
american
thorac
societi
research
statement
tabl
clark
et
al
ip
encompass
spectrum
disord
includ
diffus
alveolar
hemorrhag
dah
periengraft
respiratori
distress
syndrom
perd
acut
idiopath
interstiti
pneumon
chemotherapyrel
lung
injuri
diagnosi
howev
often
one
exclus
infecti
pneumon
sepsi
syndrom
cardiac
failur
iatrogen
fluid
overload
potenti
exhibit
similar
clinic
present
cumul
incid
ip
first
day
allogen
hct
rang
median
onset
day
posthct
mortal
rate
within
day
diagnosi
panoskaltsismortari
et
al
fukuda
et
al
sakaguchi
et
al
yanik
et
al
ip
report
pediatr
allogen
transplant
median
onset
day
posttranspl
sakaguchi
et
al
longterm
surviv
affect
children
poor
trm
significantli
higher
affect
nonaffect
patient
trm
vs
p
sakaguchi
et
al
diffus
alveolar
hemorrhag
dah
subset
ip
gener
develop
time
neutrophil
recoveri
earli
posthct
period
immedi
posthct
period
character
progress
short
breath
cough
hypoxemia
without
fever
afessa
et
al
robbin
et
al
lewi
et
al
metcalf
et
al
classic
dah
defin
demonstr
progress
bloodier
aliquot
bal
fluid
success
salin
lavag
frank
hemoptysi
rare
robbin
et
al
mortal
dah
may
high
despit
aggress
treatment
system
corticosteroid
death
usual
occur
within
week
diagnosi
lewi
et
al
small
case
seri
suggest
high
dose
solumehol
gmday
could
effect
treatment
dah
chao
et
al
retrospect
studi
suggest
addit
aminocapro
acid
high
dose
corticosteroid
could
benefit
treatment
dah
wanko
et
al
patient
dah
microorgan
isol
blood
bal
fluid
tracheal
aspir
within
week
alveolar
hemorrhag
majhail
colleagu
compar
patient
dah
infectionassoci
alveolar
hemorrhag
present
similar
clinic
radiograph
find
set
progress
bloodier
bal
fluid
follow
allogen
hct
majhail
et
al
alveolar
hemorrhag
either
infecti
noninfecti
caus
extrem
poor
outcom
follow
therapi
convent
agent
includ
steroid
majhail
et
al
periengraft
respiratori
distress
syndrom
perd
also
fall
within
definit
ip
afessa
et
al
perd
character
fever
dyspnea
hypoxemia
definit
occur
within
day
neutrophil
engraft
capizzi
et
al
wilczynski
et
al
bhalla
et
al
although
perd
autolog
hct
appear
similar
ip
allogen
hct
respect
clinic
present
time
onset
perdsip
follow
autolog
transplant
differ
sharpli
perdsip
allogen
set
significantli
improv
outcom
autolog
set
kantrow
et
al
yanik
et
al
cahil
et
al
capizzi
et
al
potenti
etiolog
risk
factor
ip
includ
direct
toxic
hct
condit
regimen
occult
pulmonari
infect
immunolog
factor
relat
acut
gvhd
crawford
et
al
weiner
et
al
kantrow
et
al
atkinson
et
al
della
volp
et
al
crawford
hackman
sakaguchi
et
al
particular
cumul
incid
ip
significantli
less
follow
use
reduc
intens
condit
regimen
compar
convent
myeloabl
regimen
fukuda
et
al
acut
gvhd
often
preced
ip
suggest
possibl
causal
relationship
two
disord
crawford
hackman
bortin
et
al
beschorn
et
al
weiner
et
al
crawford
et
al
kantrow
et
al
afessa
et
al
howev
although
ip
may
correl
presenc
acut
gvhd
necessarili
correl
sever
gvhd
consist
clinic
report
ip
allogen
hct
recipi
whose
sign
symptom
gvhd
mild
absent
yanik
et
al
schultz
et
al
curti
et
al
clark
et
al
holland
et
al
schwarer
et
al
histor
lung
recogn
classic
target
organ
gvhd
specif
role
alloreact
donor
tlymphocyt
pathogenesi
ip
consider
debat
epitheli
apoptosi
usual
attribut
tcellmedi
injuri
consid
pathognomon
acut
gvhd
although
identifi
lung
mani
patient
ip
yousem
beschorn
et
al
epitheli
apoptosi
consist
observ
allogen
hct
recipi
lung
dysfunct
base
upon
murin
model
pathogenesi
ip
appear
complex
interplay
solubl
inflammatori
mediat
cytokin
lipopolysaccharid
lp
inflammatori
chemokin
donorderiv
effector
cell
accessori
cell
myeloid
pulmonari
macrophag
resid
epitheli
endotheli
cell
signific
increas
total
number
lymphocyt
macrophag
neutrophil
bronchoalveolar
space
cook
et
al
increas
vascular
permeabl
plu
elev
level
inflammatori
cytokin
note
lung
tissu
bal
fluid
murin
model
clinic
sampl
patient
ip
clark
et
al
shankar
cohen
cook
et
al
piguet
et
al
direct
role
develop
ip
establish
use
strategi
either
neutral
effect
piguet
et
al
cook
et
al
use
mice
hct
donor
cook
et
al
hildebrandt
et
al
administr
rhtnfrfc
solubl
dimer
tnfbind
protein
time
endotoxin
challeng
mice
effect
prevent
ipsassoci
lung
injuri
set
cook
et
al
studi
use
genet
alter
mice
shown
ip
depend
upon
donorderiv
rather
hostderiv
donor
accessori
cell
macrophagemonocyt
cell
significantli
contribut
lung
injuri
tcell
compon
predomin
hildebrandt
et
al
like
contribut
develop
ip
direct
indirect
mechan
addit
directli
cytotox
increas
express
inflammatori
chemokin
hildebrandt
et
al
major
histocompat
complex
mhc
antigen
modul
leukocyt
migrat
facilit
cellmedi
cytotox
includ
endotheli
cell
injuri
common
featur
ip
gerbitz
et
al
strategi
neutral
experiment
model
complet
abrog
lung
injuri
piguet
et
al
cook
et
al
clark
et
al
hildebrandt
et
al
suggest
inflammatori
cellular
mechan
besid
may
also
contribut
develop
ip
exampl
nitric
oxid
reactiv
oxygen
speci
also
implic
develop
lung
injuri
hct
particularli
set
myeloabl
condit
haddad
et
al
panoskaltsismortari
et
al
qureshi
et
al
analysi
plasma
bal
fluid
protein
profil
patient
ip
show
addit
increas
level
solubl
receptor
signific
elev
cytokin
protein
involv
lp
cascad
lbp
along
sever
inflammatori
chemokin
mig
regul
leukocyt
recruit
site
inflamm
also
evid
yanik
et
al
treatment
option
ip
histor
combin
support
care
measur
includ
supplement
oxygen
support
diuret
broadspectrum
antimicrobi
agent
intraven
corticosteroid
kantrow
et
al
yanik
et
al
tizon
et
al
highdos
corticosteroid
therapi
mgkgday
methylprednisolon
equival
shown
improv
outcom
compar
lower
dose
corticosteroid
mgkgday
fukuda
et
al
recent
role
tnf
inhibit
manag
ip
investig
pilot
studi
univers
michigan
examin
use
solubl
tnfbind
agent
etanercept
treatment
patient
met
diagnost
criteria
ip
cours
therapi
given
strict
definit
use
defin
respons
complet
cessat
oxygen
support
within
day
therapi
onset
respons
note
ten
subject
surviv
within
therapi
period
fukuda
et
al
yanik
et
al
retrospect
review
patient
treat
either
corticosteroid
alon
n
versu
corticosteroid
plu
etanercept
n
similarli
note
high
respons
rate
etanercept
arm
overal
surviv
significantli
higher
patient
treat
corticosteroid
plu
etanercept
day
vs
year
vs
p
follow
onset
ip
tizon
et
al
advanc
support
care
includ
earli
institut
continu
venoven
hemofiltr
may
provid
addit
help
improv
surviv
prospect
studi
address
treatment
ip
clinic
trial
progress
base
upon
encourag
result
larger
phase
ii
pediatr
phase
iii
adult
trial
recent
complet
within
bone
marrow
transplant
clinic
trial
network
phase
iii
children
oncolog
group
phase
ii
bronchiol
obliteran
syndrom
initi
describ
form
chronic
lung
injuri
follow
allogen
transplant
remain
one
perplex
posttranspl
condit
manag
holland
et
al
crawford
et
al
clinic
cours
highli
variabl
rang
gradual
declin
lung
function
year
rapid
deterior
sever
month
incid
bo
vari
follow
allogen
hct
wide
rang
like
reflect
nonuniform
diagnost
criteria
use
defin
condit
afessa
et
al
william
et
al
disord
associ
airflow
obstruct
pulmonari
function
test
pft
declin
forc
expiratori
volum
vital
capac
fvc
ratio
requir
diagnost
purpos
earli
stage
bo
character
small
airway
inflamm
lymphocyt
bronchiti
ultim
progress
fibrin
obliter
bronchiolar
lumen
schwarer
et
al
urbanski
et
al
cook
yanik
respiratori
symptom
includ
cough
dyspnea
wheez
mani
patient
remain
asymptomat
despit
show
sign
moder
sever
airway
obstruct
pft
clark
et
al
holland
et
al
chest
radiograph
often
normal
except
sign
hyperinfl
curti
et
al
holland
et
al
schwarer
et
al
likewis
chest
ct
find
rang
normal
earli
cours
diseas
extens
peribronchi
inflamm
bronchiectasi
signific
air
trap
diffus
parenchym
hypoattenu
later
time
point
schultz
et
al
ooi
et
al
one
studi
demonstr
high
resolut
ct
scan
bo
character
central
airway
dilat
degre
correl
decrement
lung
function
distinct
central
airway
narrow
observ
emphysema
asthma
gazourian
et
al
clinic
cours
bo
vari
mild
sever
necrot
bronchiol
rapid
declin
respiratori
function
holland
et
al
schultz
et
al
sullivan
et
al
sanchez
et
al
curti
et
al
clark
et
al
nih
consensu
statement
diagnosi
stage
chronic
gvhd
includ
strict
diagnost
criteria
bo
subsequ
propos
modif
improv
identif
bo
patient
william
et
al
filipovich
et
al
tabl
studi
publish
prior
public
use
variou
definit
diseas
respons
therapi
make
difficult
translat
previou
result
current
era
fred
hutchinson
cancer
research
center
recent
util
nih
criteria
identifi
incid
risk
factor
mortal
bo
follow
allogen
hct
au
et
al
overal
incid
bo
high
patient
chronic
gvhd
median
time
diagnosi
day
posthct
chronic
gvhd
present
patient
identifi
bo
lower
baselin
circul
igg
level
predict
bo
onset
previous
report
risk
factor
bo
includ
busulfanbas
regimen
peripher
stem
cell
donor
sourc
methotrex
gvhd
prophylaxi
viral
pneumon
posthct
hla
mismatch
diseas
statu
use
myeloabl
regimen
predict
bo
report
holland
et
al
schultz
et
al
clark
et
al
chien
et
al
unfortun
wherea
risk
factor
bo
identifi
clear
predictor
outcom
report
therapi
bo
remain
challeng
recogn
standard
therapi
establish
prognosi
bo
poor
surviv
rate
chien
et
al
even
answer
seemingli
basic
question
yet
determin
point
therapi
start
bal
transbronchi
surgic
lung
biopsi
requir
prior
start
treatment
respons
defin
european
gvhd
consensu
confer
summar
diagnost
criteria
treatment
option
pulmonari
manifest
chronic
gvhd
particular
focu
bo
hildebrandt
et
al
pft
recommend
prehct
everi
month
first
year
posttranspl
everi
month
thereaft
obstruct
chang
note
pft
highresolut
comput
tomographi
hrct
inspiratori
expiratori
imag
recommend
assess
radiograph
sign
bo
includ
air
trap
bronchial
wall
thicken
bronchiectasi
fig
degre
obstruct
chang
declin
would
warrant
hrct
specifi
though
mani
center
declin
would
typic
initi
hrct
especi
predict
system
topic
inhal
corticosteroid
mtor
inhibitor
extracorpor
photopheresi
ecp
imatinib
azithromycin
montelukast
combin
topic
corticosteroidbronchodil
util
vari
degre
success
hildebrandt
et
al
bo
treatment
option
base
upon
prospect
clinic
trial
ratjen
et
al
khalid
et
al
couriel
et
al
yanik
et
al
system
topic
corticosteroid
becom
commonplac
manag
bo
support
small
case
report
observ
studi
ratjen
et
al
ishii
et
al
bergeron
et
al
bashoura
et
al
three
retrospect
studi
support
use
inhal
corticosteroid
bergeron
et
al
bashoura
et
al
norman
et
al
combin
system
plu
inhal
corticosteroid
examin
studi
one
trial
repetit
cours
oral
methylprednisolon
mgkgday
plu
inhal
budesonid
led
diseas
stabil
patient
ratjen
et
al
combin
inhal
steroid
plu
longact
bronchodil
budesonideformoterol
report
patient
bo
clinic
improv
note
patient
respons
seen
mean
month
follow
onset
therapi
bergeron
et
al
anoth
case
seri
use
inhal
fluticason
azithromycin
montelukast
fam
therapi
use
spare
system
corticosteroid
usag
eight
patient
bo
norman
et
al
chronic
gvhd
consortium
begun
enrol
patient
clinic
trial
investig
use
fam
therapi
newli
diagnos
bo
use
macrolid
antibiot
azithromycin
frontlin
therapi
bo
widespread
transplant
commun
though
base
upon
singl
report
eight
hct
patient
receiv
cours
therapi
khalid
et
al
subject
undergo
pretherapi
bal
thu
question
whether
subsequ
respons
secondari
antiinflammatori
antimicrobi
effect
agent
publish
report
justifi
use
azithromycin
bo
prevent
observ
studi
patient
bo
follow
lung
allograft
experienc
improv
month
azithromycin
therapi
gottlieb
et
al
presenc
neutrophilia
pretherapi
bal
posit
predictor
subsequ
respons
also
suggest
mechanist
role
azithromycin
clinic
set
gottlieb
et
al
publish
report
benefit
ecp
bo
follow
hct
even
less
compel
couriel
et
al
lucid
et
al
child
et
al
one
focus
patient
bo
posthct
lucid
et
al
stabil
report
six
nine
patient
retrospect
report
compar
valu
prior
ecp
therapi
lucid
et
al
phase
ii
clinic
trial
use
etanercept
treatment
chronic
lung
injuri
posthct
report
yanik
et
al
etanercept
administ
patient
either
bo
n
restrict
lung
diseas
n
nih
consensu
criteria
use
defin
cohort
patient
bo
subject
bo
respons
defin
improv
within
week
therapi
complet
respons
note
patient
bo
differ
respons
base
upon
sever
pulmonari
diseas
studi
onset
therapi
well
toler
infecti
complic
estim
os
ci
patient
respond
therapi
yanik
et
al
studi
deserv
particular
notic
use
strict
elig
respons
criteria
patient
underw
pre
posttherapi
bal
hrct
plasma
biomark
analysi
pft
addit
pft
perform
monthli
therapi
chang
adjuv
immunesuppress
therapi
allow
within
initi
day
therapi
yanik
et
al
lack
defin
respons
criteria
greatli
limit
abil
compar
therapi
strategi
bo
improv
use
etanercept
bo
trial
even
equat
improv
perform
best
measur
airway
obstruct
respons
would
chang
vital
capac
svc
serv
better
indic
respons
small
airway
diseas
au
et
al
qualiti
life
qol
assess
includ
respons
analysi
etanercept
trial
uniqu
valid
qualiti
life
qol
instrument
addit
use
assess
patient
perform
therapi
howev
differ
qol
outcom
measur
pretherapi
vs
posttherapi
note
subject
respond
respond
therapi
yanik
unpublish
observ
develop
bo
like
involv
initi
insult
lung
parenchyma
follow
ongo
inflammatori
process
involv
immun
effector
cell
resid
cell
pulmonari
vascular
endothelium
interstitium
much
knowledg
regard
pathogenesi
bo
base
upon
observ
made
lung
allograft
recipi
data
gener
murin
tracheal
transplant
model
strong
immun
respons
note
rat
heterotop
lung
allograft
respons
present
even
fibrosi
airway
obliter
complet
boehler
et
al
sever
group
shown
enhanc
express
lung
allograft
reject
belperio
et
al
elssner
et
al
fattalgerman
et
al
elgamel
et
al
addit
reveal
critic
role
rant
develop
experiment
bo
belperio
et
al
ultim
advanc
manag
bo
requir
improv
understand
basic
pathophysiolog
disord
murin
model
bo
report
peribronchiolar
inflamm
airway
resist
mice
mimick
human
model
panoskaltsismortari
et
al
srinivasan
et
al
potenti
benefit
murin
model
remain
elucid
term
improv
understand
enigmat
disord
design
optim
treatment
strategi
bronchiol
obliteran
organ
pneumonia
boop
first
describ
allogen
hct
earli
present
acut
bilater
airspac
diseas
within
first
month
posttranspl
thirman
et
al
mathew
et
al
fig
contrast
bo
bronchiolar
damag
predomin
boop
primarili
alveolar
disord
disord
character
extens
infiltr
granul
tissu
within
alveoli
fibroblast
matrix
loos
connect
tissu
deposit
pathophysiolog
poorli
understood
though
strong
associ
acut
andor
chronic
gvhd
freudenberg
et
al
jinta
et
al
possibl
link
hla
yotsumoto
et
al
decreas
incid
follow
tcelldeplet
hct
ditschkowski
et
al
support
alloimmun
mechan
avoid
confus
bo
disord
renam
cryptogen
organ
pneumonia
cop
pulmonari
commun
though
consensu
diagnost
criteria
lack
incid
boop
estim
base
upon
singl
institut
report
freudenberg
et
al
jinta
et
al
contrast
ip
bo
boop
typic
present
fever
dyspnea
nonproduct
cough
pft
reveal
restrict
defect
fvc
tabl
hrct
reveal
peripher
air
space
consolid
groundglass
nodular
opac
commonli
identifi
lee
et
al
pipavath
et
al
given
clinic
present
radiograph
find
infecti
etiolog
must
rule
patient
despit
collect
support
diagnosi
boop
base
upon
clinic
find
radiograph
present
transbronchi
surgic
lung
biopsi
approach
still
consid
gold
standard
diagnosi
alasali
et
al
well
standard
treatment
boop
clinic
trial
current
list
clinicaltrialsgov
base
limit
retrospect
review
system
corticosteroid
mgkgday
would
consid
treatment
choic
prolong
treatment
cours
recommend
secondari
high
rate
recurr
taper
thirman
et
al
mathew
et
al
freudenberg
et
al
jinta
et
al
report
respons
rate
overal
surviv
approxim
freudenberg
et
al
jinta
et
al
overal
understand
boop
limit
consensu
diagnost
criteria
lack
prospect
trial
minim
understand
underli
pathophysiolog
three
disord
ip
bo
boop
postul
caus
alloimmun
injuri
howev
alloreact
would
select
target
interstitium
bronchoalveoli
ip
bronchiolar
structur
bo
alveoli
boop
remain
poorli
understood
hepat
venoocclus
diseas
vod
also
known
sinusoid
obstruct
syndrom
so
potenti
lifethreaten
complic
hct
hepat
vodso
affect
adult
pediatr
popul
allogen
autolog
graft
recipi
higher
incid
allogen
set
richardson
et
al
carrera
onset
vodso
well
describ
within
first
day
hct
richardson
et
al
though
later
occurr
report
character
clinic
featur
includ
hepatomegali
jaundic
weight
gain
ascit
carrera
et
al
coppel
et
al
vodso
report
occur
patient
follow
hct
carrera
et
al
although
incid
rate
may
high
higherrisk
patient
underli
liver
diseas
certain
specif
drug
exposur
includ
gemtuzumab
ozogamicin
sirolimu
depend
upon
diagnost
criteria
use
carrera
et
al
coppel
et
al
sever
vodso
typic
associ
multiorgan
failur
mof
high
mortal
rate
carrera
et
al
coppel
et
al
even
among
patient
moder
vodso
mortal
rate
still
estim
approxim
mcdonald
et
al
vodso
thought
trigger
activ
damag
sinusoid
endotheli
cell
sec
zone
hepat
acinu
due
condit
regimenmedi
injuri
guglielmelli
et
al
shown
figur
exposur
sec
condit
radiat
toxic
metabolit
chemotherapi
lead
sec
injuri
activ
activ
sec
express
cytokin
eg
adhes
molecul
eg
result
activ
proinflammatori
pathway
damag
endothelium
coppel
et
al
lead
loss
endotheli
wall
fenestra
format
gap
sec
panel
b
carrera
consequ
red
blood
cell
leukocyt
cellular
debri
extravas
space
diss
caus
progress
extralumin
compress
narrow
sinusoid
carrera
coppel
et
al
bearman
dissect
endotheli
cell
could
embol
downstream
occlud
sinusoid
panel
c
carrera
addit
injuri
sec
sinusoid
also
associ
procoagul
hypofibrinolyt
state
contribut
fibrin
deposit
clot
format
situ
narrow
sinusoid
guglielmelli
et
al
coppel
et
al
bearman
togeth
effect
reduc
hepat
venou
outflow
lead
postsinusoid
hypertens
central
venular
occlus
hepat
enlarg
capsular
distens
sever
case
portal
venou
flow
revers
hepatoren
syndrom
lead
multiorgan
failur
mof
death
carrera
fig
diagnosi
vodso
made
base
clinic
criteria
two
establish
system
seattl
criteria
bearman
baltimor
criteria
corbacioglu
et
al
jone
et
al
richardson
et
al
seattl
criteria
requir
least
two
clinic
featur
includ
jaundic
pain
hepatomegali
ascit
andor
unexplain
weight
gain
within
day
transplant
bearman
corbacioglu
et
al
baltimor
criteria
specifi
elev
bilirubin
level
least
mgdl
two
follow
characterist
hepatomegali
ascit
least
weight
gain
day
posthct
baltimor
criteria
valid
accord
histopatholog
featur
well
outcom
bearman
jone
et
al
vodso
present
wide
clinic
spectrum
convent
divid
mild
moder
sever
diseas
mcdonald
et
al
mild
vodso
consid
diseas
meet
diagnost
criteria
requir
specif
treatment
fluid
excess
medic
hepat
pain
selflimit
cours
moder
vodso
reveal
evid
liver
injuri
need
activ
treatment
fluid
excess
medic
hepat
pain
usual
resolv
complet
sever
vodso
defin
associ
mof
sever
hyperbilirubinemia
rapid
weight
gain
high
mortal
rate
delev
et
al
although
sever
biomark
endotheli
injuri
describ
literatur
includ
plasminogen
activ
inhibitor
nurnberg
et
al
salat
et
al
laboratori
marker
valid
diagnost
marker
vodso
retrospect
analys
presenc
multiorgan
failur
emerg
use
marker
vodso
sever
date
bearman
model
develop
estim
risk
develop
sever
vodso
base
bilirubin
level
percentag
weight
gain
design
time
frame
hct
model
demonstr
util
predict
vodso
sever
howev
bearman
model
develop
cohort
patient
develop
vodso
within
day
hct
specif
condit
regimen
gener
applic
condit
regimen
later
time
frame
posthct
limit
carrera
et
al
coppel
et
al
bearman
et
al
context
sensit
specif
biomark
assay
need
could
guid
diseas
prognost
manag
candid
marker
studi
none
yet
defin
current
manag
vodso
consist
primarili
support
care
fluid
manag
adequ
oxygen
transfusion
support
given
minim
ischem
liver
injuri
plu
avoid
known
hepatonephrotoxin
delev
et
al
richardson
et
al
use
tissu
plasminogen
activ
without
heparin
evalu
number
studi
howev
result
gener
disappoint
approxim
onethird
patient
show
respons
thrombolyt
therapi
although
sever
hemorrhag
common
therapi
life
threaten
surviv
advantag
appar
delev
et
al
tabl
although
agent
date
approv
treatment
vodso
either
usa
europ
investig
drug
defibrotid
df
shown
promis
result
clinic
trial
date
df
use
patient
worldwid
demonstr
signific
safeti
toler
low
rate
drugrel
hemorrhag
ref
gentium
announc
submiss
market
author
applic
defibrotid
european
medicin
agenc
df
polydispers
oligonucleotid
fibrinolyt
properti
signific
system
anticoagul
shown
protect
effect
micro
macrovascular
endothelium
use
df
treatment
vodso
support
number
larg
clinic
trial
show
df
improv
complet
respons
cr
surviv
recent
multicent
random
phase
ii
studi
establish
effect
df
dose
mgkgday
given
divid
dose
intraven
everi
hour
richardson
et
al
tabl
efficaci
df
treatment
vodso
initi
demonstr
retrospect
studi
patient
vodso
plu
mof
show
complet
resolut
vodso
eight
patient
six
surviv
longer
day
signific
bleed
observ
richardson
et
al
number
trial
subsequ
confirm
efficaci
df
european
multicent
compassionateus
studi
demonstr
cr
rate
treat
patient
chopra
et
al
pivot
phase
iii
trial
df
patient
vodso
plu
mof
show
superior
cr
rate
df
group
compar
histor
control
treat
without
df
vs
respect
adjust
p
lower
mortal
rate
vs
respect
adjust
p
fda
permit
access
df
usa
investig
new
drug
ind
expand
access
treatment
protocol
patient
vodso
plu
mof
analysi
patient
enrol
decemb
march
us
center
compassionateus
studi
reveal
cr
rate
day
posthct
day
overal
surviv
richardson
et
al
promis
result
observ
df
vodso
treatment
trial
led
investig
use
prophylaxi
vodso
follow
hct
number
prospect
histor
control
trial
report
benefit
df
prophylaxi
pediatr
patient
high
risk
develop
vodso
cappelli
et
al
corbacioglu
et
al
qureshi
et
al
studi
also
support
recent
prospect
multicent
phase
iiiii
studi
europ
corbacioglu
trial
children
year
undergo
myeloabl
hct
random
receiv
either
prophylact
df
condit
day
posthct
prophylaxi
control
group
intenttotreat
analysi
reduct
vodso
day
posthct
patient
receiv
prophylact
df
compar
control
vs
p
note
mortal
day
four
time
higher
patient
develop
vodso
compar
without
vodso
vs
p
interestingli
enough
incid
acut
gvhd
also
significantli
lower
df
prophylaxi
arm
observ
consist
similar
find
treatment
studi
richardson
et
al
despit
promis
result
clinic
trial
df
treatment
prevent
vodso
day
mortal
vodso
remain
unaccept
high
import
earli
intervent
key
recent
clinic
observ
indic
delay
initi
vodso
treatment
associ
wors
outcom
richardson
et
al
role
df
vodso
manag
may
fact
optim
use
earli
diseas
prophylaxi
addit
prospect
studi
vodso
prevent
plan
adult
hct
popul
specif
highrisk
set
elev
von
willebrand
factor
thrombomodulin
eselectin
solubl
earli
allogen
transplant
may
use
predict
vodso
patient
receiv
sirolimu
cutler
et
al
gvhd
prophylaxi
could
lead
preemptiv
treatment
prevent
trial
base
biomark
richardson
et
al
final
addit
therapi
low
molecular
weight
heparin
nacetyl
cystein
antithrombin
iii
novel
antithrombot
may
warrant
investig
combin
df
richardson
et
al
ho
et
al
